CTLA4 and melanoma: As recently described, immune checkpoint inhibitors (ICIs), including CTLA4 inhibitors and PD1 and PD-L1 inhibitors, have been approved for treating many cancers, such as kidney cancer, melanoma, urothelial cancer and lung cancer, and have achieved good outcomes [36].